Skip to main content
. 2022 Aug 17;6(16):4773–4781. doi: 10.1182/bloodadvances.2022007112

Figure 1.

Figure 1.

Clinical and lymph node responses. Kaplan-Meier curves for PFS (A) and overall survival in patients treated with siltuximab or placebo (B). Cumulative incidence curves for time to normalization of lymph node response (C) and time to durable symptomatic response (D) in patients treated with siltuximab or placebo. BSC, best supportive care; NR, not reached.